The recent report of the Secondary Prevention of Small Subcortical Strokes (SPS3) trial, a randomized controlled clinical trial of secondary prevention of stroke targeting systolic blood pressures (BPs) <130 versus 130 to 149 mm Hg in patients with recent but not acute subcortical lacunar stroke, and the associated Comment conclude that "Although the reduction in stroke was not significant, our results support that in patients with recent lacunar stroke, the use of a systolic-blood-pressure target of less than 130 mm Hg is likely to be beneficial." Indeed, the Comment underlined that "the SPS3 trial was underpowered to identify or exclude confidently a slight, but nevertheless clinically important, increase in serious complications of hypotension with systolic blood pressure lower than 130 mm Hg." However, the cover of August 10 to 16, 2013 issue of The Lancet that carries the article on SPS3 and the associated Comment reads "The implications of SPS3 are that clinicians should endeavour to achieve and maintain systolic blood pressures lower than 130 mm Hg in patients who have survived 2 weeks or more after subcortical lacunar ischemic stroke." This assertion is essentially based on the consistency of results across subgroups, the consistency of results (19% reduction in events) with other studies of primary or secondary prevention of different types of stroke, at similar differences of systolic BP between groups, in this particular trial 11 mm Hg between the achieved BP of the high-target group (138 mm Hg) and the low-target group (127 mm Hg), among the 3020 subjects with MRI-proven lacunar strokes followed for 3 to 6 years.

However, in an era of "evidence-based medicine," the BP target after results that are not statistically significant in a trial possibly underpowered to detect either benefit or harm should remain in a situation of equipoise, with cautious recommendations that stress that the evidence is weak. The results were consistent across subgroups, and specifically hemorrhagic stroke prevention did achieve statistical significance (P=0.03); nevertheless, the latter was a secondary end point, and the primary end point of prevention of all strokes was nonsignificant (P=0.08).

The vascular biology underlying lacunar strokes may differ from that of other types of stroke such that BP lowering may be less effective in prevention of repeat stroke post lacunar stroke certainly than hemorrhagic stroke as shown in this trial and other strokes or all strokes as demonstrated in the Perindopril Protection against Recurrent Stroke Study (PROGRESS) and in a small group of subjects in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Recurrence of lacunar strokes may be more sensitive to more important lowering of BP (J-curve effect), eliminating the benefit of lower BPs seen for strokes in general. The Comment in The Lancet brings up the greater use of \( \beta \)-blockers in the lower target group than in the higher target group. Indeed, enhanced visit-to-visit variability in systolic BP. However, there was increased use of calcium channel blockers in the lower target group. Calcium channel blockers reduce visit-to-visit BP variability and could accordingly counteract the action of excess use of \( \beta \)-blockers. But all this remains speculative. The important fact is that the primary end point did not achieve statistical significance.

It would seem that it is premature for blanket statements recommending treatment targets to appear in the article, the
Response to Optimum Blood Pressure Target After Lacunar Stroke: Con Side of the Argument

Graeme J. Hankey, Ben Lacey

We agree with Schiffrin that the Secondary Prevention of Small Subcortical Strokes (SPS3) trial primary end point did not reach the arbitrary threshold of statistical significance of P<0.05. However, we also agree with Hackshaw and Kirkwood that borderline significance in the primary end point of trials does not necessarily mean that the intervention is not effective. Borderline P values, such as in SPS3, can occur when there is a clinically meaningful treatment effect but a large SE because of an insufficient number of outcome events. The SPS3 trial was powered to reliably identify a reduction in the relative risk of recurrent stroke by 25%, but not by the observed 19%. Nevertheless, the SPS3 results still offer some evidence of a beneficial effect in targeting a systolic blood pressure <130 mm Hg compared with 130 to 149 mm Hg; the 95% confidence intervals indicate that recurrent stroke may be reduced by as much as 36% or increased by as much as 3%.

We also agree with Schiffrin that the evidence from the SPS3 trial is weak, if it is interpreted in isolation. However, the evidence from SPS3 is compelling when it is interpreted in the context of meta-analyses of large numbers of cohort studies and clinical trials that have not identified a threshold below which blood pressure lowering is not associated with a reduced risk of stroke, down to ≥115/75 mm Hg. Further, there is no strong evidence to indicate that this varies in different subtypes of stroke. Although awaiting the outcome of future randomized trials, the totality of evidence suggests that targeting a systolic blood pressure <130 mm Hg is likely to be safe and more effective than a systolic blood pressure of 130 to 149 mm Hg in patients with recent (but not acute) lacunar ischemic stroke.

References
Optimum Blood Pressure Target After Lacunar Stroke: Con Side of the Argument
Ernesto L. Schiffrin

Hypertension. 2014;63:923-924; originally published online March 3, 2014;
doi: 10.1161/HYPERTENSIONAHA.113.02529
Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2014 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://hyper.ahajournals.org/content/63/5/923